#USA #Salt Lake City #TCI Biotech #Tony Hatori #Alan Roberts

TCI Biotech Strengthens Its Global Team

In a significant move to enhance its market footprint, TCI Biotech, a prominent player in the health and wellness biotech sector, has unveiled key additions to its leadership team. The recent appointments of Tony Hatori as Vice President of Sales and Alan Roberts as Strategic Consultant for the U.S. market reflect the company's strategic dedication to driving global growth and innovation.

Leadership Changes to Drive Global Expansion

On September 9, 2025, TCI Biotech announced these pivotal leadership roles aimed at accelerating its business objectives. Tony Hatori brings a wealth of experience to the organization, having held high-ranking positions within major consumer health companies. With over three decades of leadership under his belt, including roles as CEO at Avon Japan and President at Zeria USA, Mr. Hatori is poised to leverage his extensive knowledge in market development and brand partnerships for TCI.

Similarly, Alan Roberts, known for founding Nutrition Innovation, will apply his deep expertise in product development and regulatory affairs to enhance TCI's operations in the U.S. His previous collaborations with major brands have provided him with a profound understanding of market dynamics, essential for navigating the competitive landscape in health foods and supplements.

Emphasis on Innovation and Adaptability

TCI Biotech is not only focusing on leadership talent but is also revamping its operational strategy. The firm is transitioning towards an asset-light manufacturing model. This approach is particularly beneficial in a volatile market where supply chain flexibility is paramount. By establishing production facilities across strategic locations in Asia, Europe, and North America, TCI can quickly adapt to varying consumer demands and regulatory environments.

The company's operations span crucial markets including the U.S., China, Japan, Thailand, and India, ensuring not just a globally integrated structure but a responsive supply chain that supports its business objectives.

Reinforcing Corporate Strategy

With these appointments, TCI Biotech reaffirms its commitment to its three-pillar strategy:
1. Science-Driven Innovation: Focusing on clinically validated biotechnology that underpins the development of differentiated formulations, TCI aims to position itself at the forefront of scientific advancement in health supplements.
2. Building Global Customer Trust: TCI emphasizes the importance of developing long-lasting partnerships based on transparency and reliability, which are critical in fostering customer trust.
3. Asset-Light Manufacturing: By utilizing a flexible manufacturing model, TCI ensures that it can swiftly respond to market changes and customer needs, showcasing resilience in its operations.

As TCI Biotech embarks on this new chapter, the foundation laid by the newly appointed leaders sets the stage for an exciting period of growth and innovation. Their expertise is invaluable in driving forward TCI's mission to deliver high-quality, scientifically-backed health products worldwide.

For more insights about TCI Biotech and its strategic initiatives, visit www.tci-bio.com.

• ---

This article contains forward-looking statements regarding TCI's growth strategies and corporate activities, which are subject to risks and uncertainties.